Ace Therapeutics provides robust intraocular pressure (IOP) measurement services using animal models of ophthalmic diseases to help you quantify the effects of candidate agents, characterize dose-response relationships, and track longitudinal IOP dynamics. Our standardized workflows support consistent collection across study timepoints, minimize variability from handling and experimental conditions, and provide clean datasets with summary statistics and key figures to support your in vivo efficacy and mechanism studies.
IOP is a practical and sensitive functional readout in animal models of ocular disease. It provides a direct, quantitative way to track disease progression and evaluate how test compounds influence ocular physiology over time. Because IOP can vary with study timing and experimental conditions, standardized workflows and consistent scheduling are essential for generating comparable, reproducible results. When paired with complementary ocular endpoints within the same in vivo study, IOP data strengthens both efficacy assessment and mechanism-focused research.
Fig. 1. Schematic diagram about drug applications and IOP measurements. (Kim SH, et al., 2023)
IOP monitoring is often a key readout in preclinical ophthalmology programs. At Ace Therapeutics, we incorporate IOP measurement into our ocular animal model services to help clients track changes before and after test article dosing and throughout follow-up. With well-defined protocols and experienced technicians, we generate consistent IOP measurement data across the full study timeline. Our IOP measurement capabilities cover single timepoint assessments, longitudinal monitoring, and diurnal profiling within an end-to-end in vivo study workflow.
We measure IOP at key study timepoints, from baseline through post-dosing follow-up, to enable clear group comparisons and time-course evaluation.
We monitor IOP repeatedly across the entire study timeline, from days to months, to track disease progression or treatment response trends and assess the durability of pharmacological effects.
We support diurnal IOP profiling with scheduled measurements across predefined time windows to capture fluctuation patterns and strengthen group comparisons.
If you are planning a preclinical ophthalmology study that requires robust IOP endpoints, Ace Therapeutics can support you with integrated ocular animal model development services and comprehensive IOP measurement across single-timepoint, longitudinal, and diurnal profiling throughout your in vivo study. Contact us to discuss your research objectives and next steps.
References